{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:23:06Z","timestamp":1768004586483,"version":"3.49.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T00:00:00Z","timestamp":1530835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00535-018-1479-6","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T11:29:22Z","timestamp":1530876562000},"page":"989-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["The state of the art on treatment of Crohn\u2019s disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Hai Yun","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Chien","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066\u201378.","journal-title":"N Engl J Med"},{"key":"1479_CR2","doi-asserted-by":"publisher","first-page":"46.e42","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46.e42\u201354.e42 [quiz e30].","journal-title":"Gastroenterology"},{"key":"1479_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2018","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769\u201378.","journal-title":"Lancet"},{"key":"1479_CR4","first-page":"158.e2","volume":"145","author":"SC Ng","year":"2013","unstructured":"Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn\u2019s and colitis epidemiology study. Gastroenterology. 2013;145:158.e2\u2013165.e2.","journal-title":"Gastroenterology"},{"key":"1479_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.gastro.2015.11.029","volume":"150","author":"GG Kaplan","year":"2016","unstructured":"Kaplan GG, Jess T. The changing landscape of inflammatory bowel disease: east meets west. Gastroenterology. 2016;150:24\u20136.","journal-title":"Gastroenterology"},{"key":"1479_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00535-009-0057-3","volume":"44","author":"K Asakura","year":"2009","unstructured":"Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn\u2019s disease in Japan. J Gastroenterol. 2009;44:659\u201365.","journal-title":"J Gastroenterol"},{"key":"1479_CR7","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1097\/MIB.0000000000000846","volume":"22","author":"SC Ng","year":"2016","unstructured":"Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: results from a territory-wide population-based registry in Hong Kong. Inflamm Bowel Dis. 2016;22:1954\u201360.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ibd.20310","volume":"14","author":"SK Yang","year":"2008","unstructured":"Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986\u20132005: a KASID study. Inflamm Bowel Dis. 2008;14:542\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME Valk van der","year":"2014","unstructured":"van der Valk ME, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut. 2014;63:72\u20139.","journal-title":"Gut"},{"key":"1479_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, et al. The natural history of adult Crohn\u2019s disease in population-based cohorts. Am j gastroenterol. 2010;105:289.","journal-title":"Am j gastroenterol"},{"key":"1479_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/gut.2005.084061","volume":"55","author":"FL Wolters","year":"2006","unstructured":"Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn\u2019s disease. Gut. 2006;55:1124\u201330.","journal-title":"Gut"},{"key":"1479_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","volume":"5","author":"IC Solberg","year":"2007","unstructured":"Solberg IC, Vatn MH, H\u00f8ie O, et al. Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1479_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/ecco-jcc\/jjx138","volume":"12","author":"B Lo","year":"2018","unstructured":"Lo B, Vester-Andersen M, Vind I, et al. Changes in disease behaviour and location in patients with Crohn\u2019s disease after seven years of follow-up: a Danish population-based inception cohort. J Crohn\u2019s Colitis. 2018;12(3):265\u2013272.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1479_CR14","doi-asserted-by":"publisher","first-page":"190.e11","DOI":"10.1016\/j.cgh.2017.05.047","volume":"16","author":"HY Shi","year":"2018","unstructured":"Shi HY, Levy AN, Trivedi HD, et al. Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies. Clin Gastroenterol Hepatol. 2018;16:190.e11\u2013197e11.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR15","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/gutjnl-2013-305607","volume":"63","author":"C Rungoe","year":"2014","unstructured":"Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979\u20132011. Gut. 2014;63(10):1607\u201316.","journal-title":"Gut"},{"key":"1479_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","volume":"10","author":"V Annese","year":"2016","unstructured":"Annese V, Duricova D, Gower-Rousseau C, et al. Impact of new treatments on hospitalisation, surgery, infection, and mortality in ibd: a focus paper by the epidemiology committee of ECCO. J Crohns Colitis. 2016;10:216\u201325.","journal-title":"J Crohns Colitis"},{"key":"1479_CR17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn\u2019s disease activity index: National Cooperative Crohn\u2019s Disease Study. Gastroenterology. 1976;70:439\u201344.","journal-title":"Gastroenterology"},{"key":"1479_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/gast.2002.31072","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease. Gastroenterology. 2002;122:512\u201330.","journal-title":"Gastroenterology"},{"key":"1479_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2016","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J. Crohn\u2019s Colitis. 2016;11:3\u201325.","journal-title":"J. Crohn\u2019s Colitis"},{"key":"1479_CR20","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1111\/j.1572-0241.2008.02176.x","volume":"103","author":"KT Thia","year":"2008","unstructured":"Thia KT, Sandborn WJ, Lewis JD, et al. Defining the optimal response criteria for the Crohn\u2019s disease activity index for induction studies in patients with mildly to moderately active Crohn\u2019s disease. Am. J. gastroenterol. 2008;103:3123.","journal-title":"Am. J. gastroenterol."},{"issue":"4","key":"1479_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","volume":"61","author":"CN Bernstein","year":"2012","unstructured":"Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn\u2019s disease. Gut. 2012;61(4):622\u20139.","journal-title":"Gut"},{"key":"1479_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","volume":"138","author":"F Baert","year":"2010","unstructured":"Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease. Gastroenterology. 2010;138:463\u20138.","journal-title":"Gastroenterology"},{"key":"1479_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. The Lancet. 2008;371:660\u20137.","journal-title":"The Lancet"},{"key":"1479_CR24","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1097\/MIB.0000000000000816","volume":"22","author":"AR Reinink","year":"2016","unstructured":"Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2016;22:1859\u201369.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","volume":"63","author":"L Peyrin-Biroulet","year":"2014","unstructured":"Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial. Gut. 2014;63:88\u201395.","journal-title":"Gut"},{"key":"1479_CR26","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1097\/MIB.0000000000000649","volume":"22","author":"AM Buchner","year":"2016","unstructured":"Buchner AM, Lichtenstein GR. How to assess and document endoscopies in ibd patients by including standard scoring systems. Inflamm Bowel Dis. 2016;22:1010\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gut.30.7.983","volume":"30","author":"J-Y Mary","year":"1989","unstructured":"Mary J-Y, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn\u2019s disease: a prospective multicentre study. Groupe d\u2019Etudes therapeutiques des affections inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983\u20139.","journal-title":"Gut"},{"key":"1479_CR28","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324\u201338.","journal-title":"Am J Gastroenterol"},{"key":"1479_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno M, D\u2019Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc. 2004;60:505\u201312.","journal-title":"Gastrointest Endosc"},{"key":"1479_CR30","first-page":"348.e17","volume":"14","author":"L Peyrin-Biroulet","year":"2016","unstructured":"Peyrin-Biroulet L, Panes J, Sandborn WJ, et al. defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016;14:348.e17\u2013354.e17.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR31","doi-asserted-by":"publisher","first-page":"978.e5","DOI":"10.1053\/j.gastro.2013.08.010","volume":"145","author":"M Ferrante","year":"2013","unstructured":"Ferrante M, Colombel JF, Sandborn WJ, et al. Validation of endoscopic activity scores in patients with Crohn\u2019s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145:978.e5\u2013986.e5.","journal-title":"Gastroenterology"},{"key":"1479_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","volume":"99","author":"P Rutgeerts","year":"1990","unstructured":"Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn\u2019s disease. Gastroenterology. 1990;99:956\u201363.","journal-title":"Gastroenterology"},{"key":"1479_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.crohns.2013.02.020","volume":"7","author":"J Panes","year":"2013","unstructured":"Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohn\u2019s Colitis. 2013;7:556\u201385.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1479_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1136\/gut.2008.167957","volume":"58","author":"J Rimola","year":"2009","unstructured":"Rimola J, Rodr\u00edguez S, Garc\u00eda-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn\u2019s disease. Gut. 2009;58:1113\u201320.","journal-title":"Gut"},{"key":"1479_CR35","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/ibd.21551","volume":"17","author":"J Rimola","year":"2010","unstructured":"Rimola J, Ord\u00e1s I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn\u2019s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2010;17:1759\u201368.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-4-1","volume":"4","author":"Health UDo, Evaluation HSFCfD Research","year":"2006","unstructured":"Health UDo, Evaluation HSFCfD Research, et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:1\u201320.","journal-title":"Health Qual Life Outcomes"},{"key":"1479_CR37","doi-asserted-by":"publisher","first-page":"1246.e6","DOI":"10.1016\/j.cgh.2014.02.016","volume":"12","author":"N Williet","year":"2014","unstructured":"Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246.e6\u20131256.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR38","doi-asserted-by":"publisher","first-page":"1042.e2","DOI":"10.1016\/j.cgh.2013.09.006","volume":"13","author":"G Bouguen","year":"2015","unstructured":"Bouguen G, Levesque BG, Feagan BG, et al. Treat to target: a proposed new paradigm for the management of Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13:1042.e2\u20131050.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR39","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/rheumatology\/keq195","volume":"49","author":"LG Schipper","year":"2010","unstructured":"Schipper LG, Van Hulst LT, Grol R, et al. Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. Rheumatology. 2010;49:2154\u201364.","journal-title":"Rheumatology"},{"key":"1479_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/ajg.2014.357","volume":"110","author":"CN Bernstein","year":"2015","unstructured":"Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114\u201326.","journal-title":"Am J Gastroenterol"},{"key":"1479_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jgh.12958","volume":"31","author":"CJ Ooi","year":"2016","unstructured":"Ooi CJ, Makharia GK, Hilmi I, et al. Asia-Pacific consensus statements on Crohn\u2019s disease. Part 2: management. J Gastroenterol Hepatol. 2016;31:56\u201368.","journal-title":"J Gastroenterol Hepatol"},{"key":"1479_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2016","unstructured":"Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 2: surgical management and special situations. J Crohn\u2019s Colitis. 2016;11:135\u201349.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1479_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MIB.0000000000001023","volume":"23","author":"S Coward","year":"2017","unstructured":"Coward S, Kuenzig ME, Hazlewood G, et al. Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn\u2019s disease: a Bayesian network meta-analysis. Inflamm Bowel Dis. 2017;23:461\u201372.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.crohns.2012.06.010","volume":"7","author":"T Nunes","year":"2013","unstructured":"Nunes T, Barreiro-de Acosta M, Marin-Jimenez I, et al. Oral locally active steroids in inflammatory bowel disease. J Crohns Colitis. 2013;7:183\u201391.","journal-title":"J Crohns Colitis"},{"key":"1479_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","author":"N Chande","year":"2015","unstructured":"Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2015. \n                    https:\/\/doi.org\/10.1002\/14651858\n                    \n                  .","journal-title":"Cochrane Libr."},{"key":"1479_CR46","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","volume":"149","author":"J Torres","year":"2015","unstructured":"Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149:1716\u201330.","journal-title":"Gastroenterology"},{"key":"1479_CR47","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(78)92524-2","volume":"312","author":"D O\u2019Donoghue","year":"1978","unstructured":"O\u2019Donoghue D, Dawson A, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn\u2019s disease. The Lancet. 1978;312:955\u20137.","journal-title":"The Lancet"},{"key":"1479_CR48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/j.1365-2036.2004.01944.x","volume":"19","author":"M Vilien","year":"2004","unstructured":"Vilien M, Dahlerup J, Munck L, et al. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn\u2019s disease: increased relapse rate the following year. Aliment Pharmacol Ther. 2004;19:1147\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR49","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","volume":"128","author":"M L\u00e9mann","year":"2005","unstructured":"L\u00e9mann M, Mary J-Y, Colombel J-F, et al. A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812\u20138.","journal-title":"Gastroenterology"},{"key":"1479_CR50","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","volume":"60","author":"HH Wenzl","year":"2015","unstructured":"Wenzl HH, Primas C, Novacek G, et al. Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn\u2019s disease. Dig Dis Sci. 2015;60:1414\u201323.","journal-title":"Dig Dis Sci"},{"key":"1479_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/flgastro-2016-100738","volume":"9","author":"B Warner","year":"2018","unstructured":"Warner B, Johnston E, Arenas-Hernandez M, et al. A practical guide to thiopurine prescribing and monitoring in IBD. Frontline Gastroenterol. 2018;9:10\u20135.","journal-title":"Frontline Gastroenterol"},{"key":"1479_CR52","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/apt.12511","volume":"38","author":"NA Kennedy","year":"2013","unstructured":"Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther. 2013;38:1255\u201366.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR53","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ibd.21221","volume":"16","author":"B Jharap","year":"2010","unstructured":"Jharap B, Seinen ML, De Boer N, et al. Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts. Inflamm Bowel Dis. 2010;16:1541\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR54","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.3748\/wjg.v21.i25.7795","volume":"21","author":"GW Moran","year":"2015","unstructured":"Moran GW, Dubeau M-F, Kaplan GG, et al. Clinical predictors of thiopurine-related adverse events in Crohn\u2019s disease. World J Gastroenterol WJG. 2015;21:7795.","journal-title":"World J Gastroenterol WJG"},{"key":"1479_CR55","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1586\/17474124.2015.1039987","volume":"9","author":"R Goldberg","year":"2015","unstructured":"Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015;9:891\u2013900.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1479_CR56","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. The Lancet. 2009;374:1617\u201325.","journal-title":"The Lancet"},{"key":"1479_CR57","doi-asserted-by":"publisher","first-page":"1621.e5","DOI":"10.1053\/j.gastro.2011.06.050","volume":"141","author":"L Peyrin-Biroulet","year":"2011","unstructured":"Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621.e5\u20131628.e2.","journal-title":"Gastroenterology"},{"key":"1479_CR58","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.cgh.2014.02.026","volume":"12","author":"A Lopez","year":"2014","unstructured":"Lopez A, Mounier M, Bouvier A-M, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1324\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR59","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/apt.13466","volume":"43","author":"A Bourrier","year":"2016","unstructured":"Bourrier A, Carrat F, Colombel JF, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016;43:252\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR60","doi-asserted-by":"publisher","first-page":"847.e4","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847.e4\u2013858.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","volume":"12","author":"G Doherty","year":"2017","unstructured":"Doherty G, Katsanos KH, Burisch J, et al. European Crohn\u2019s and colitis organisation topical review on treatment withdrawal [\u2018exit strategies\u2019] in inflammatory bowel disease. J Crohn\u2019s Colitis. 2017;12:17\u201331.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1479_CR62","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1136\/flgastro-2015-100681","volume":"7","author":"Y Gonzalez-Lama","year":"2016","unstructured":"Gonzalez-Lama Y, Gisbert JP. Monitoring thiopurine metabolites in inflammatory bowel disease. Frontline Gastroenterol. 2016;7:301\u20137.","journal-title":"Frontline Gastroenterol"},{"key":"1479_CR63","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/2040622315579063","volume":"6","author":"RM Goel","year":"2015","unstructured":"Goel RM, Blaker P, Mentzer A, et al. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis. 2015;6:138\u201346.","journal-title":"Ther Adv Chronic Dis"},{"key":"1479_CR64","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ng.3060","volume":"46","author":"S-K Yang","year":"2014","unstructured":"Yang S-K, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46:1017.","journal-title":"Nat Genet"},{"key":"1479_CR65","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/MIB.0000000000000589","volume":"22","author":"HH Herfarth","year":"2016","unstructured":"Herfarth HH, Kappelman MD, Long MD, et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22:224\u201333.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR66","doi-asserted-by":"publisher","first-page":"966e2","DOI":"10.1016\/j.cgh.2015.10.034","volume":"14","author":"M Simon","year":"2016","unstructured":"Simon M, Pariente B, Lambert J, et al. Long-term outcomes of thalidomide therapy for adults with refractory Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2016;14:966e2\u2013972.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR67","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.2013.280777","volume":"310","author":"M Lazzerini","year":"2013","unstructured":"Lazzerini M, Martelossi S, Magazzu G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA. 2013;310:2164\u201373.","journal-title":"JAMA"},{"key":"1479_CR68","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/1756283X17698910","volume":"10","author":"Y He","year":"2017","unstructured":"He Y, Mao R, Chen F, et al. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn\u2019s disease: a prospective open-label study. Therap adv gastroenterol. 2017;10:397\u2013406.","journal-title":"Therap adv gastroenterol"},{"key":"1479_CR69","doi-asserted-by":"publisher","first-page":"e4239","DOI":"10.1097\/MD.0000000000004239","volume":"95","author":"M Bramuzzo","year":"2016","unstructured":"Bramuzzo M, Ventura A, Martelossi S, et al. Thalidomide for inflammatory bowel disease: Systematic review. Med (Baltimore). 2016;95:e4239.","journal-title":"Med (Baltimore)"},{"key":"1479_CR70","doi-asserted-by":"publisher","first-page":"1382.e1","DOI":"10.1016\/j.cgh.2017.02.029","volume":"15","author":"M Lazzerini","year":"2017","unstructured":"Lazzerini M, Villanacci V, Pellegrin MC, et al. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol. 2017;15:1382.e1\u20131389.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR71","doi-asserted-by":"publisher","first-page":"j2505","DOI":"10.1136\/bmj.j2505","volume":"357","author":"BL Cohen","year":"2017","unstructured":"Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.","journal-title":"BMJ"},{"key":"1479_CR72","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMct1209614","volume":"369","author":"OH Nielsen","year":"2013","unstructured":"Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369:754\u201362.","journal-title":"N Engl J Med"},{"key":"1479_CR73","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn\u2019s disease. N Engl J Med. 1997;337:1029\u201336.","journal-title":"N Engl J Med"},{"key":"1479_CR74","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti\u2013tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I Trial. Gastroenterology. 2006;130:323\u201333.","journal-title":"Gastroenterology"},{"key":"1479_CR75","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829\u201338.","journal-title":"Ann Intern Med"},{"key":"1479_CR76","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","volume":"6","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease. J Crohn\u2019s Colitis. 2012;6:160\u201373.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1479_CR77","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","volume":"129","author":"S Schreiber","year":"2005","unstructured":"Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn\u2019s disease. Gastroenterology. 2005;129:807\u201318.","journal-title":"Gastroenterology"},{"key":"1479_CR78","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u201338.","journal-title":"N Engl J Med"},{"key":"1479_CR79","first-page":"670.e3","volume":"9","author":"WJ Sandborn","year":"2011","unstructured":"Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670.e3\u2013678.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR80","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. The Lancet. 2002;359:1541\u20139.","journal-title":"The Lancet"},{"key":"1479_CR81","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology. 2004;126:402\u201313.","journal-title":"Gastroenterology"},{"key":"1479_CR82","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"1479_CR83","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20139.","journal-title":"Gut"},{"key":"1479_CR84","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S Schreiber","year":"2007","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn\u2019s disease. N Engl J Med. 2007;357:239\u201350.","journal-title":"N Engl J Med"},{"key":"1479_CR85","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/apt.12749","volume":"39","author":"R Stidham","year":"2014","unstructured":"Stidham R, Lee T, Higgins P, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;39:1349\u201362.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR86","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","volume":"45","author":"A Cholapranee","year":"2017","unstructured":"Cholapranee A, Hazlewood G, Kaplan G, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291\u2013302.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/apt.13847","volume":"45","author":"EJ Mao","year":"2017","unstructured":"Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45:3\u201313.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR88","first-page":"64.e2","volume":"148","author":"S Singh","year":"2015","unstructured":"Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn\u2019s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148:64.e2\u201376.e2.","journal-title":"Gastroenterology"},{"key":"1479_CR89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/apt.13445","volume":"43","author":"N Ding","year":"2016","unstructured":"Ding N, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease\u2014algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR90","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","volume":"52","author":"Y Qiu","year":"2017","unstructured":"Qiu Y, B-l Chen, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease. J Gastroenterol. 2017;52:535\u201354.","journal-title":"J Gastroenterol"},{"key":"1479_CR91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","volume":"12","author":"S Danese","year":"2015","unstructured":"Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1479_CR92","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/ecco-jcc\/jjw007","volume":"10","author":"C Moore","year":"2016","unstructured":"Moore C, Corbett G, Moss AC. Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohn\u2019s Colitis. 2016;10:619\u201325.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1479_CR93","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med"},{"key":"1479_CR94","first-page":"344.e5","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015;148:344.e5\u2013354.e5.","journal-title":"Gastroenterology"},{"key":"1479_CR95","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apt.13862","volume":"45","author":"B Ungar","year":"2017","unstructured":"Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45:276\u201382.","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"1479_CR96","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.cgh.2015.06.034","volume":"3","author":"JL Jones","year":"2015","unstructured":"Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn\u2019s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;3(13):2233\u201340.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1479_CR97","first-page":"835.e6","volume":"153","author":"NV Casteele","year":"2017","unstructured":"Casteele NV, Herfarth H, Katz J, et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835.e6\u2013857.e6.","journal-title":"Gastroenterology"},{"key":"1479_CR98","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","volume":"153","author":"JD Feuerstein","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827\u201334.","journal-title":"Gastroenterology"},{"key":"1479_CR99","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","volume":"11","author":"FS Velayos","year":"2013","unstructured":"Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn\u2019s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654\u201366.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1479_CR100","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","volume":"63","author":"C Steenholdt","year":"2014","unstructured":"Steenholdt C, Brynskov J, Thomsen O\u00d8, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919\u201327.","journal-title":"Gut"},{"key":"1479_CR101","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14740338.2016.1145653","volume":"15","author":"K Papamichael","year":"2016","unstructured":"Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn\u2019s disease. Expert Opin Drug Saf. 2016;15:493\u2013501.","journal-title":"Expert Opin Drug Saf"},{"key":"1479_CR102","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","volume":"6","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR103","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ajg.2012.89","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J gastroenterol. 2012;107:1051.","journal-title":"Am J gastroenterol"},{"key":"1479_CR104","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ibd\/izx072","volume":"24","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn\u2019s disease: more than 13\u00a0years of real-world experience. Inflamm Bowel Dis. 2018;24:490\u2013501.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR105","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","volume":"7","author":"CA Siegel","year":"2009","unstructured":"Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti\u2013tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR106","doi-asserted-by":"publisher","first-page":"941.e2","DOI":"10.1053\/j.gastro.2013.12.025","volume":"146","author":"MT Osterman","year":"2014","unstructured":"Osterman MT, Sandborn WJ, Colombel J-F, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease. Gastroenterology. 2014;146:941.e2\u2013949.e2.","journal-title":"Gastroenterology"},{"key":"1479_CR107","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/apt.13547","volume":"43","author":"NA Kennedy","year":"2016","unstructured":"Kennedy NA, Warner B, Johnston EL, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43:910\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR108","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u201321.","journal-title":"N Engl J Med"},{"key":"1479_CR109","doi-asserted-by":"publisher","first-page":"618.e3","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618.e3\u2013627.e2.","journal-title":"Gastroenterology"},{"key":"1479_CR110","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","volume":"21","author":"E Shelton","year":"2015","unstructured":"Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21:2879\u201385.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR111","doi-asserted-by":"publisher","first-page":"1593.e2","DOI":"10.1016\/j.cgh.2016.02.016","volume":"14","author":"A Amiot","year":"2016","unstructured":"Amiot A, Grimaud J-C, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:1593.e2\u20131601.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR112","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/apt.13594","volume":"43","author":"D Baumgart","year":"2016","unstructured":"Baumgart D, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2013a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090\u2013102.","journal-title":"Aliment Pharmacol Ther"},{"key":"1479_CR113","doi-asserted-by":"publisher","first-page":"1385.e10","DOI":"10.1016\/j.cgh.2016.04.039","volume":"14","author":"S Bonovas","year":"2016","unstructured":"Bonovas S, Fiorino G, Allocca M, et al. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385.e10\u20131397.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1479_CR114","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.gtc.2017.05.013","volume":"46","author":"P Deepak","year":"2017","unstructured":"Deepak P, Sandborn WJ. Ustekinumab and Anti-Interleukin-23 Agents in Crohn\u2019s Disease. Gastroenterol Clin North Am. 2017;46:603\u201326.","journal-title":"Gastroenterol Clin North Am"},{"key":"1479_CR115","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360.","journal-title":"N Engl J Med"},{"key":"1479_CR116","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1365-2133.2012.11142.x","volume":"167","author":"TF Tsai","year":"2012","unstructured":"Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167:1145\u201352.","journal-title":"Br J Dermatol"},{"key":"1479_CR117","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","volume":"14","author":"S Ben-Horin","year":"2016","unstructured":"Ben-Horin S, Vande Casteele N, Schreiber S, et al. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. Clin Gastroenterol Hepatol. 2016;14:1685\u201396.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1479_CR118","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11938-018-0177-z","volume":"16","author":"FI Scott","year":"2018","unstructured":"Scott FI, Lichtenstein GR. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Curr Treat Options Gastroenterol. 2018;16(1):147\u201367.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"1479_CR119","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","volume":"23","author":"G Fiorino","year":"2017","unstructured":"Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23:233\u201343.","journal-title":"Inflamm Bowel Dis"},{"key":"1479_CR120","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. The Lancet. 2017;389:2304\u201316.","journal-title":"The Lancet"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-018-1479-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1479-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T23:21:48Z","timestamp":1562368908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-018-1479-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,6]]},"references-count":120,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1479-6","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,6]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}